Memphasys Stock

Equities

MEM

AU000000MEM5

Biotechnology & Medical Research

Market Closed - Australian S.E. 12:14:16 2024-05-17 am EDT 5-day change 1st Jan Change
0.008 AUD 0.00% Intraday chart for Memphasys 0.00% -33.33%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Dynamic Chart
1 week-11.11%
Current month-11.11%
1 month-11.11%
3 months-20.00%
6 months-16.50%
Current year-33.33%
More quotes
1 week
0.01
Extreme 0.007
0.01
1 month
0.01
Extreme 0.007
0.01
3 years
0.01
Extreme 0.007
0.11
5 years
0.01
Extreme 0.007
0.15
10 years
0.01
Extreme 0.007
0.66
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-03-26
Director of Finance/CFO - -
Chief Operating Officer - 23-04-23
Members of the board TitleAgeSince
Chairman - 22-04-25
Director/Board Member 59 20-03-11
Chief Executive Officer - 23-03-26
More insiders
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW